ContraVir Pharmaceuticals (CTRV) Starts Presentation at Biotech Showcase Conference

ContraVir Pharmaceuticals (NASDAQ: CTRV) is developing targeted antiviral therapies with two drug candidates in clinical studies. The first drug candidate, FV-100, is now in phase 3 trials. It is being developed for the treatment of herpes zoster, or shingles, and shingle pain. ContraVir is also developing CMX157, a highly potent analog of the successful antiviral drug tenofovir DF (Viread). For more information, visit the company’s website at www.contravir.com.